The Phase 3 clinical trial showed that enfortumab vedotin in combination with pembrolizumab nearly doubled median overall survival (OS) and signficantly extended progression-free survival (PFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback